Abstract
Despite of the fact that current anticancer chemotherapeutics have many beneficial achievements, there is an urgent need for new efficient therapies. A new type of drugs which are extensively investigated are immunotoxinshybrid proteins that consist of cytotoxic component and second part which is responsible for selective binding to the receptors on tumor cells. Unfortunately, this group of therapeutics still has many drawbacks. There is a strong demand for research on a new substances and develo-ping targeted therapy strategies. In the present study we tested VapC toxin derived from prokaryotic addictive modules as a potential component in the construction of immunotoxins. Investigated fusion protein consists of VapC toxin has RNase activity and digests total RNA in various treatment times. Moreover, studied protein displays proapoptotic properties and cell cycle arrest in selected cancer cell lines.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
